GMAB catalysts
Catalysts and events linked to GMAB, newest first.
GMAB stock catalysts and risks
Latest published review: 2026-10-20
| Development | Transmission channel | Evidence | Condition to watch |
|---|---|---|---|
| Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial 2026-10-04 · Up | clinical pipeline derisking and commercial net present value revision | Source explicitly reports Genmab's Phase 2 RAINFOL-01 trial results. | Not recorded |
| Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial 2026-10-04 · Up | clinical pipeline derisking and ADC market opportunity | Genmab reported 45.9% ORR and 9.5 months mPFS in Phase 2 RAINFOL-01 trial. | Not recorded |
| Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial 2026-10-04 · Up | biotech pipeline net present value repricing on positive Phase 2 efficacy data | 45.9% ORR and 12.1m mDOR support regulatory pathway and peak revenue forecasts for Rina-S. | Not recorded |
| Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian Cancer 2026-10-04 · Up | biotech pipeline derisking and oncology franchise market value adjustment | Genmab announced Phase 2 results for Rina-S in platinum-resistant ovarian cancer, demonstrating a 45.9% objective response rate with a median duration of response of 12.1 months. | Not recorded |
| Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFS 2026-10-04 · Up | clinical pipeline de-risking boosting ADC portfolio NPV | Phase 2 trial shows 45.9% ORR and 9.5-month PFS in platinum-resistant ovarian cancer. | Not recorded |
| Genmab reports 45.9% ORR and 9.5-month PFS in Phase 2 platinum-resistant ovarian cancer trial 2026-10-04 · Up | pipeline net present value repricing on positive Phase 2 clinical readout | 45.9% ORR and 9.5-month median PFS reported in RAINFOL-01 trial. | Not recorded |
| Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer Trial 2026-10-04 · Up | oncology pipeline clinical asset derisking | Reported Phase 2 RAINFOL-01 ORR of 45.9% and median PFS of 9.5 months. | Not recorded |
| Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer Trial 2026-10-04 · Up | biotech pipeline valuation expansion on positive Phase 2 trial readout | 45.9% ORR and 9.5 months mPFS in platinum-resistant ovarian cancer de-risks Rina-S asset. | Not recorded |
Do these developments change your position?
Review GMAB alongside your other holdings and identify which decision deserves attention first.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
DateCardAvg 5d
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB
- 2026-10-04Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian CancerGMAB
- 2026-10-04Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFSGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-10-04Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian CancerGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian CancerGMAB
- 2026-10-04Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFSGMAB
- 2026-10-04Genmab reports 45.9% ORR and 9.5-month PFS in Phase 2 platinum-resistant ovarian cancer trialGMAB
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.